About the Company
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PTN News
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
Palatin Technologies (PTN) Company Description: Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the ...
PTN Apr 2024 2.500 put
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Palatin Techs Stock (AMEX:PTN), Quotes and News Summary
Avi Kapoor Palatin Technologies' Disappointing Data From Dry ... In Monday's Mid-Day Session Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company ...
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about ...
Palatin to tweak second PL-9643 phase III in dry eye disease
After trading as low as $2.04, shares of Palatin Technologies Inc. (NYSE:PTN) closed Feb. 28 down $1.57, or 39.7%, ending at $2.39 on word of results from the phase III pivotal Melody-1 trial with ...
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about ...
Palatin Technologies Inc.
Picking the best bond ETF can be hard with so many options available. Here's what the experts suggest focusing on.
Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about ...
Palatin Technologies Inc PTN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Palatin Technologies Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Loading the latest forecasts...